Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: [Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer. [Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administering an anti-HER3 antibody-drug conjugate.

Abstract: The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.

Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: Problem There is proposed an innovative cross-sectional structure, with an idea contrary to the conventional one, utilizing the non-reactivity between Cu and Ta (or between Ag and Nb, Ta) in a high-temperature short-time heat treatment, thus achieving (1) the suppression of the low magnetic-field instability, (2) excellent wire drawability of a precursor wire, and (3) the reduction of the cost required for the incorporation of a stabilizer. Means for Resolution There is proposed a structure having an assembly of a plurality of single wires, wherein the assembly is covered with an outer cover (skin) formed from Nb or Ta, wherein each of the single wires has an Nb/Al composite filament region which is formed from a composite of Nb and Al mixed in an Nb:Al molar ratio of 3:1, and which is covered with a partition formed from Nb or Ta, and further covered with an interfilamentary barrier formed from Cu or Ag disposed around the partition.

Abstract: A hot water supply system includes a plurality of water heaters, one of which is designated as a master, and the rest(s) of which is/are designated as (a) slave(s). A control unit that is provided for each of the water heaters operates a water heater, for which the control unit is provided, as the master or the slave, the master controls the slave(s), and the master and the slave(s) control hot water supply.

Abstract: A water heater includes one or a plurality of heat pumps that heat tap water or return water from a hot water supply part, a circulation line that supplies hot water heated in the heat pumps to the hot water supply part, and introduces the return water from the hot water supply part to the heat pumps, an incoming water pipe that joins to between the hot water supply part in the circulation line and the heat pumps and supplies the tap water, a circulation pump that returns the return water to the heat pumps and circulates the return water through the circulation line, and a control unit that controls operation or stop of the circulation pump according to driving operation time or elapsed stop time by linking a combustion process of the heat pumps.

Abstract: A precursor for a Nb3Sn superconductor wire to be manufactured by the internal diffusion method, includes a plurality of Nb-based single core wires, each of which includes a Nb-based core coated with a Cu-based coating including a Cu-based matrix, a plurality of Sn-based single core wires, each of which includes a Sn-based core coated with a Cu-based coating including a Cu-based matrix; and a cylindrical diffusion barrier including Ta or Nb, in which the plurality of Nb-based single core wires and the plurality of Sn-based single core wires are regularly disposed, wherein the plurality of Nb-based single core wires include Nb-based single core wires having a Cu/Nb ratio of 0.4 or more, wherein the Cu/Nb ratio is a cross sectional area ratio of the Cu-based coating to the Nb-based core.

Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.

Abstract: A hot water supply system includes a plurality of water heaters, one of which is designated as a master, and the rest(s) of which is/are designated as (a) slave(s). A control unit that is provided for each of the water heaters operates a water heater, for which the control unit is provided, as the master or the slave, the master controls the slave(s), and the master and the slave(s) control hot water supply.

Abstract: A hot water supply system including a water heater that includes a storage unit storing at least device information of another water heater, and performs hot water supply control by which the water heater cooperates with the other water heater, these water heaters being able to supply hot water according to a hot water supply request; one or a plurality of the other water heater that is connected to the water heater in parallel, and supplies hot water according to the hot water supply control by the water heater; communication connection means that communicably connects the water heater and the other water heater; water supply means that supplies water to the water heater and the other water heater; and hot water supply means that supplies hot water heated by the water heater and the other water heater to a hot water supply destination.

Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.

Abstract: A precursor for a Nb3Sn superconductor wire to be manufactured by the internal diffusion method, includes a plurality of Nb-based single core wires, each of which includes a Nb-based core coated with a Cu-based coating including a Cu-based matrix, a plurality of Sn-based single core wires, each of which includes a Sn-based core coated with a Cu-based coating including a Cu-based matrix; and a cylindrical diffusion barrier including Ta or Nb, in which the plurality of Nb-based single core wires and the plurality of Sn-based single core wires are regularly disposed, wherein the plurality of Nb-based single core wires include Nb-based single core wires having a Cu/Nb ratio of 0.4 or more, wherein the Cu/Nb ratio is a cross sectional area ratio of the Cu-based coating to the Nb-based core.

Abstract: A precursor for a Nb3Sn superconductor wire to be manufactured by the internal diffusion method. The precursor includes Nb-based single core wires, Sn-based single core wires, and a cylindrical diffusion barrier made of Ta or Nb. Each Nb-based single core wire includes a Nb-based core coated with a Cu-based coating made of a Cu-based matrix. Each Sn-based single core wire includes a Sn-based core coated with a Cu-based coating made of a Cu-based matrix. The Nb-based single core wires and the Sn-based single core wires are regularly disposed in the diffusion barrier. The Nb-based single core wires includes at least two kinds of Nb-based single core wires having different Cu/Nb ratios and the Cu/Nb ratio is a cross sectional area ratio of the Cu-based coating to the Nb-based core.

Abstract: This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur/gimeracil/oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene.